Welcome to our dedicated page for Telix Pharmaceuticals ADR news (Ticker: TLX), a resource for investors and traders seeking the latest updates and insights on Telix Pharmaceuticals ADR stock.
Telix Pharmaceuticals Limited (TLX) generates a steady flow of news related to its radiopharmaceutical pipeline, commercial portfolio, and global operations. As a biopharmaceutical company focused on therapeutic and diagnostic radiopharmaceuticals and associated medical technologies, its announcements often highlight progress in oncology and rare disease programs, regulatory milestones, and commercial performance.
Recent Telix news has covered precision medicine portfolio updates, including Phase 3 data for TLX591-CDx (Illuccix) in China, regulatory interactions for TLX101-CDx (Pixclara) and TLX250-CDx (Zircaix) with the U.S. Food and Drug Administration, and inclusion of TLX250-CDx in international renal imaging guidelines. The company also reports on clinical collaborations, such as its agreement with Varian to explore combining Telix’s theranostic products with external beam radiation therapy.
Investors and clinicians following TLX news can expect updates on clinical trial milestones (for example, first patient dosed in the SOLACE trial for TLX090 or in the BiPASS Phase 3 trial for prostate cancer diagnosis), as well as information on reimbursement and market access developments. Telix has announced CMS Transitional Pass-Through status and a permanent HCPCS code for Gozellix in the United States, along with country-level approvals and launches for Illuccix in Europe and the United Kingdom.
Telix also issues news on financial performance and guidance, such as quarterly revenue updates and full-year revenue outlook, and on participation in major healthcare conferences where management presents the company’s pipeline and commercial strategy. For users tracking TLX, the news stream provides insight into how Telix advances its radiopharmaceutical products from clinical development through regulatory review and commercialization across multiple regions.
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) has announced an upcoming Investor Day scheduled for June 11, 2025, in New York City. The event will run from 8:30 AM to 12:00 PM ET and will focus on growth opportunities across Telix's commercial and clinical portfolio of precision medicine and therapeutic radiopharmaceuticals.
Key presenters will include CEO Dr. Christian Behrenbruch, CMO Dr. David N. Cade, CEO Therapeutics Richard Valeix, and CEO Precision Medicine Kevin Richardson. Key Opinion Leaders will also share insights on Telix's theranostic candidates. The event is exclusively for qualified institutional investors and analysts, with advance registration required via email.
Telix Pharmaceuticals (ASX/NASDAQ: TLX) has published promising results for its FAP-targeting therapy candidate TLX400 in the Thyroid journal. The study, involving 73 heavily pre-treated patients with radioiodine-resistant (RAI-R) thyroid cancer, demonstrated encouraging efficacy with median progression-free survival of 29 months and overall survival of 32 months.
The treatment showed a 50% partial response rate with manageable adverse events, primarily hematotoxicity. TLX400's novel structure enables prolonged tumor retention while minimizing off-target uptake, potentially offering advantages over current tyrosine kinase inhibitors (TKIs) like sorafenib and lenvatinib, which can have significant side effects.
Telix Pharmaceuticals has received marketing authorization in France for Illuccix, its prostate cancer PET imaging agent. The approval by ANSM enables French healthcare facilities to access this PSMA-PET imaging technology for prostate cancer detection and management.
The approval covers three key clinical applications:
- Primary staging of high-risk prostate cancer patients
- Detection of recurrent cancer in patients with rising PSA levels
- Identification of patients suitable for PSMA-targeted therapy
Telix has partnered with IRE ELiT for marketing and promotion in France, where prostate cancer affects over 57,000 new cases annually. The technology offers superior accuracy compared to conventional imaging methods and allows on-site preparation of PSMA-PET scans, improving accessibility and reducing diagnosis delays.
Telix Pharmaceuticals (ASX/NASDAQ: TLX) reported strong Q1 2025 performance with unaudited revenue of $186 million, up 62% year-over-year and 31% quarter-over-quarter. This includes:
- $151 million from global Illuccix® sales (35% YOY increase)
- $33 million from RLS Radiopharmacies acquisition
The company reaffirmed FY 2025 revenue guidance of $770-800 million. Key developments include:
- FDA approval of Gozellix®, a next-generation PSMA-PET imaging agent
- Positive preliminary results from IPAX-Linz Phase 2 trial for brain cancer therapy
- FDA acceptance of TLX250-CDx BLA with Priority Review
- GMP accreditation for TMS Brussels South facility
The company continues to expand globally with Illuccix® receiving approvals in multiple European markets, UK, and Brazil.
Telix Pharmaceuticals (ASX/NASDAQ: TLX) has announced promising preliminary results from its Phase 2 IPAX-Linz study of TLX101 therapy for recurrent high-grade glioma. The study, combining TLX101 with external beam radiation therapy (EBRT), demonstrated a median overall survival of 12.4 months from treatment initiation, or 32.2 months from initial diagnosis.
The trial included eight patients, with treatment well-tolerated and no serious adverse events reported. Five patients had MGMT unmethylated tumors, typically associated with poor prognosis. The results corroborated the positive efficacy signal from the earlier IPAX-1 study, which showed 13 months median survival from treatment.
Telix is advancing its TLX101 development program with ongoing IPAX-2 study in front-line glioblastoma. The company has submitted for ethics approval a registration-enabling study, planning to begin patient enrollment at Australian sites in H2 2025, with U.S. sites expansion following an IND application in H1 2025.
Telix Pharmaceuticals (ASX/NASDAQ: TLX) has selected Cardinal Health (NYSE: CAH) as a commercial radiopharmaceutical distributor for Gozellix®, its FDA-approved next-generation PSMA-PET imaging agent for prostate cancer in the United States.
Cardinal Health will deploy Telix's ARTMS QUANTM Irradiation System® (QIS®) cyclotron technology for standardized, high-efficiency production of gallium-68 used with Gozellix®. The distribution agreement enables multi-Curie local production and broader availability across U.S. locations, with commercial launch planned for H1 2025.
Cardinal Health will serve as a strategic radiopharmacy distributor alongside Telix's in-house radiopharmacy network, expanding their existing partnership which includes distribution of Illuccix® and Zircaix®.